In Brief: Hoechst/Roussel Uclaf
Hoechst/Roussel Uclaf: Hoechst makes $3.6 bil. tender offer to acquire the 43.5%, or 11.8 mil. shares, of Roussel Uclaf it does not already own. The $293.90 per share offer represents a 12% premium to the average price of Roussel Uclaf over the last month. The goal of the offer, Hoechst says, is "to integrate pharmaceutical activities in a legal autonomous organization, Hoechst Marion Roussel." The move could be a prelude to listing of HMR on U.S. stock exchanges...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth